Compass Therapeutics beats Q4 EPS estimates as April data catalyst looms
Bispecific antibody data for biliary tract cancer expected in April as $209M cash position extends runway into 2028
Compass Therapeutics shares rose 2.9% on Wednesday after the clinical-stage biotechnology company reported a smaller-than-expected quarterly loss and highlighted a robust balance sheet ahead of a pivotal data readout next month.
For the fourth quarter of 2025, the Boston-based company posted a net loss of $15.7 million, or $0.09 per share, beating analyst estimates of a $0.13 loss. The stock's modest advance reflected investor focus on Compass's cash position of $209 million as of December 31, 2025—an increase of $82 million from the prior year—providing enough runway to fund operations into 2028.
The financial cushion comes at a critical juncture for Compass. The company is preparing to announce progression-free survival and overall survival data in April from its Phase 2/3 COMPANION-002 study of tovecimig, a bispecific antibody targeting both Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), in patients with biliary tract cancer.
"The prespecified event threshold of 80% overall survival events was achieved in the first quarter of 2026," Compass stated in its earnings release. "Analyses of progression-free survival and overall survival from this study are anticipated to be reported in April."
The upcoming readout represents a potential inflection point for the company. In April 2025, Compass announced that tovecimig combined with paclitaxel had already met the trial's primary endpoint, delivering an objective response rate of 17.1% compared to 5.3% for paclitaxel alone. Disease progression was notably lower at 16.2% versus 42.1% in the control arm.
Biliary tract cancer, which includes cancers of the bile ducts and gallbladder, represents a significant market opportunity. The global market for biliary tract cancer treatments was estimated at approximately $1.16 billion in 2024, with the United States accounting for roughly $700 million. The disease currently has limited treatment options in later stages, creating urgency for new therapeutic approaches.
Compass's dual-targeting strategy aims to disrupt tumor angiogenesis more effectively than single-agent approaches by simultaneously blocking DLL4/Notch and VEGF-A signaling pathways. This mechanism could position tovecimig as a new standard of care if the upcoming survival data prove positive.
For the full year 2025, Compass reported a net loss of $66.5 million, or $0.42 per share, widening from a $49.4 million loss ($0.36 per share) in 2024. The deterioration reflected increased research and development expenses, which rose 32% to $56.0 million, driven primarily by manufacturing costs for tovecimig and CTX-10726, another pipeline candidate.
General and administrative expenses increased 12% to $16.9 million, largely due to pre-commercialization expenses and advisory fees. The company's cash burn was partially offset by $129 million in net proceeds from a public offering.
Beyond tovecimig, Compass is advancing a broader pipeline that includes CTX-8371, with initial data from cohort expansions and a Phase 1 dose-escalation study expected to be presented at a major medical conference in the second quarter of 2026. Clinical data for CTX-10726 from its Phase 1 study are projected for the second half of the year, and the initiation of a Phase 2 trial for CTX-471 is expected by mid-2026.
Analysts maintain an optimistic outlook on the stock. Compass carries an average price target of $13.57, representing roughly 140% upside from current levels. The consensus rating among analysts covering the stock is "Moderate Buy," with Cantor Fitzgerald initiating coverage with an "overweight" rating in December 2025 and Canaccord Genuity setting a $13 price target in February 2026.
Compass described 2026 as a "defining year" in its corporate update, with management characterizing the upcoming tovecimig data as potentially "transformational." The company is also expanding tovecimig's testing into broader DLL4+ tumor types, with a Phase 2 study expected to begin mid-2026 following full analysis of the COMPANION-002 results.
An investigator-sponsored trial combining tovecimig with gemcitabine, cisplatin, and durvalumab for biliary tract cancer is ongoing, potentially providing additional validation for the bispecific antibody's therapeutic approach.